Search results for "INTERFERON"

showing 10 items of 963 documents

Human leucocyte antigen-A2 restricted and Mycobacterium tuberculosis 19-kDa antigen-specific CD8+ T-cell responses are oligoclonal and exhibit a T-ce…

2001

CD8+ T cells can be grouped into two different types of secretory T lymphocytes, based on the cytokine-secretion pattern upon antigen exposure: those with a T-cell cytotoxic type 1 response (Tc1), which secrete interferon-gamma (IFN-gamma), or those with a T-cell cytotoxic type 2 response, which secrete interleukin (IL)-4 and IL-10. We examined the CD8+ T-cell response directed against an immunodominant human leucocyte antigen (HLA)-A2-presented peptide derived from a 19-kDa Mycobacterium tuberculosis-associated antigen. T cells were examined by functional analysis and by T-cell receptor (TCR) complementarity-determining region 3 (CDR3)-spectratyping, which defines the complexity of a T-cel…

Receptors Antigen T-Cell alpha-betaT cellImmunologyHuman leukocyte antigenCD8-Positive T-LymphocytesBiologyLymphocyte ActivationEpitopeCell LineInterferon-gammaAntigenHLA-A2 AntigenmedicineHumansImmunology and AllergyCytotoxic T cellAntigen-presenting cellTuberculosis PulmonaryAntigens BacterialImmunodominant EpitopesT-cell receptorGranulocyte-Macrophage Colony-Stimulating FactorMycobacterium tuberculosisOriginal ArticlesComplementarity Determining RegionsMolecular biologyPeptide FragmentsClone Cellsmedicine.anatomical_structureImmunologyInterleukin-4CD8Immunology
researchProduct

Soluble interleukin-6 receptor (sIL-6R) makes IL-6R negative T cell line respond to IL-6: it inhibits TNF production

2000

The receptor for interleukin-6 (IL-6) consists of two subunits: a ligand specific IL-6Ralpha and gp130 that is responsible for signal-transduction. A soluble form of the ligand specific chain was described that when complexed to IL-6 is capable of binding to the membrane-bound gp130 subunit and thus can elicit signal-transduction. This soluble receptor can act on cells that express only the gp130 but not the ligand-specific subunit of the IL-6R. This phenomenon, called trans-signaling, introduced a novel aspect of cytokine action. In this study we examined the response of Jurkat cells, that are known not to express IL-6Ralpha, to IL-6, the soluble IL-6 receptor (sIL-6R) and a covalent compl…

Recombinant Fusion ProteinsT-Lymphocytesmedicine.medical_treatmentT cellImmunologyBiologyJurkat cellsCell LineInterferon-gammaJurkat CellsAntigens CDCytokine Receptor gp130medicineHumansImmunology and AllergyInterferon gammaElméleti orvostudományokReceptorLymphotoxin-alphaMembrane GlycoproteinsInterleukin-6Tumor Necrosis Factor-alphaReceptors InterleukinOrvostudományokLigand (biochemistry)Glycoprotein 130Receptors Interleukin-6Molecular biologyCytokinemedicine.anatomical_structureSolubilityTumor necrosis factor alphamedicine.drug
researchProduct

Specific Regulation of T Helper Cell 1–mediated Murine Colitis by CEACAM1

2004

Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) is a cell surface molecule that has been proposed to negatively regulate T cell function. We have shown that CEACAM1 is associated with specific regulation of T helper cell (Th)1 pathways, T-bet–mediated Th1 cytokine signaling, and Th1-mediated immunopathology in vivo. Mice treated with anti–mouse CEACAM1-specific monoclonal antibody (mAb) CC1 during the effector phase exhibited a reduced severity of trinitrobenzene sulfonic acid colitis in association with decreased interferon (IFN)-γ production. Although oxazolone colitis has been reported as Th2 mediated, mice treated with the CC1 mAb or a CEACAM1-Fc chimeric protein…

Recombinant Fusion Proteinsmedicine.medical_treatmentT cellImmunologyBiologyArticleOxazoloneInterferon-gammaMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAntigeninflammatory bowel diseaseInterferonmedicineAnimalsImmunology and AllergyColitisCell adhesionCEACAM1030304 developmental biologyInflammationMice KnockoutMice Inbred BALB C0303 health sciencesT cell immunityOxazoloneAntibodies MonoclonalT-Lymphocytes Helper-InducerT helper cellTh1 CellsColitismedicine.diseaseMolecular biologyCarcinoembryonic AntigenImmunoglobulin Fc Fragments3. Good healthMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureCytokinechemistry030220 oncology & carcinogenesisFemaleTh1 cytokineInterleukin-1hapten-induced colitismedicine.drugJournal of Experimental Medicine
researchProduct

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

Prognostic indicators in pediatric clinically isolated syndrome

2017

To assess prognostic factors for a second clinical attack and a first disability worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of Multiple Sclerosis (MS) patients. Objective: To assess prognostic factors for a second clinical attack and a first disability-worsening event in pediatric clinically isolated syndrome (pCIS) suggestive of multiple sclerosis (MS) patients. Methods: A cohort of 770 pCIS patients was followed up for at least 10 years. Cox proportional hazard models and Recursive Partitioning and Amalgamation (RECPAM) tree-regression were used to analyze data. Results: In pCIS, female sex and a multifocal onset were risk factors for a second clinical att…

RegistrieMaleMultiple SclerosisAdolescentAdolescent; Age of Onset; Child; Demyelinating Diseases; Female; Follow-Up Studies; Humans; Male; Multiple Sclerosis; Prognosis; Retrospective Studies; Risk Factors; Disease Progression; Registries; Neurology; Neurology (clinical)PrognosiONSET MULTIPLE-SCLEROSISCHILDHOODCHILDRENPARACLINICAL FEATURESDISABILITY PROGRESSIONNOFollow-Up StudieRisk FactorsRetrospective Studieprognostic indicatorsMultiple Sclerosipediatric multiple sclerosis prognosis indicatorsHumansRegistriesAge of OnsetChildOPTIC NEURITISRetrospective StudiesRisk FactorDemyelinating DiseaseNATURAL-HISTORYPrognosismultiple sclerosis clinically isolated syndrome prognostic indicatorsNeurologyTRANSVERSE MYELITISclinically isolated syndromeINTERFERON BETA-1BDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)FOLLOW-UPDemyelinating DiseasesFollow-Up StudiesHuman
researchProduct

The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells.

2007

Inducible nitric-oxide synthase (iNOS) has been identified as a marker and mediator of disease in human colonic inflammation and carcinogenesis. Accordingly, identification of mediators that trigger iNOS in colon carcinoma/epithelial cells is an important topic of current research. Here we demonstrate that interleukin (IL)-22, a newly described member of the IL-10 cytokine family, potently synergizes with interferon (IFN)-gamma for iNOS expression in human DLD-1 colon carcinoma cells. Detection of both IL-22 receptor chains and STAT3 phosphorylation proved robust IL-22 responsiveness of these cells. Short interfering RNA technology identified STAT3 as being crucial for up-regulation of iNOS…

STAT3 Transcription Factormedicine.medical_treatmentNitric Oxide Synthase Type IIBiologymedicine.disease_causeBiochemistryGene Expression Regulation EnzymologicInterleukin 22InterferonmedicineHumansRNA MessengerRNA NeoplasmSTAT3Promoter Regions GeneticMolecular BiologyInflammationInterleukinsNF-kappa BInterleukinCell BiologyTransfectionReceptors InterleukinMolecular biologyNeoplasm ProteinsGene Expression Regulation NeoplasticCytokineSTAT1 Transcription FactorColonic Neoplasmsbiology.proteinCancer researchCytokinesIntercellular Signaling Peptides and ProteinsTumor necrosis factor alphaImmunotherapyCaco-2 CellsCarcinogenesismedicine.drugSignal TransductionThe Journal of biological chemistry
researchProduct

The early immune response in the liver of BALB/c mice infected with S. typhimurium.

2000

Gram-negative bacteria acquired through gastrointestinal infection can be a serious cause for the development of septic shock especially in immunosuppressed patients. Thus, the aim of this study was to examine the early events of the immune reaction against S. typhimurium. Bacteria were injected into mice at different concentrations. Four animals from each group were killed at five different points of time. Liver cytokine mRNA expression was determined by semiquantitative rt-PCR and liver histology was examined. Serum cytokine levels of interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-4 and IL-10 were determined. intravenous (i.v.) infection with 109 bacteri…

Salmonella typhimuriumTime FactorsImmunologyGene ExpressionPolymerase Chain ReactionBALB/cProinflammatory cytokineSepsisMiceImmune systemInterferonmedicineAnimalsRNA MessengerMice Inbred BALB CSalmonella Infections AnimalbiologySeptic shockInterleukinGeneral Medicinemedicine.diseasebiology.organism_classificationLiverImmunologyCytokinesTumor necrosis factor alphaFemalemedicine.drugScandinavian journal of immunology
researchProduct

Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model.

2001

Abstract Background & Aims: The ability to induce cytotoxic T cells is considered an important feature of a candidate hepatitis C virus (HCV) vaccine. We used an oral immunization strategy with attenuated HCV-NS3–transformed Salmonella typhimurium to deliver DNA directly to the gut-associated lymphoid tissue. Methods: HLA-A2.1 transgenic mice were immunized once with transformed attenuated Salmonella . HCV-specific CD8 + T cells were analyzed in vitro as well as in vivo by challenge of mice with recombinant HCV-NS3 vaccinia virus. Results: Salmonella (10 8 colony-forming units; 20 μg plasmid DNA) induced cytotoxic and IFN-γ–producing CD8 + T cells specific for the immunodominant epitope NS3…

Salmonella typhimuriumViral Hepatitis VaccinesSalmonellavirusesAdministration OralMice TransgenicHepacivirusViral Nonstructural Proteinsmedicine.disease_causeMajor histocompatibility complexEpitopeVirusMicrobiologychemistry.chemical_compoundInterferon-gammaMiceInterferonHLA-A2 AntigenmedicineVaccines DNACytotoxic T cellAnimalsVaccines SyntheticHepatologybiologyGastroenterologyvirus diseasesbiochemical phenomena metabolism and nutritionVirologydigestive system diseaseschemistrybiology.proteinImmunizationVacciniaCD8medicine.drugT-Lymphocytes CytotoxicGastroenterology
researchProduct

Searching for wheat plants with low toxicity in celiac disease: Between direct toxicity and immunologic activation.

2009

Abstract Background Natural or induced variations in the noxiousness of gluten proteins for celiac disease (CD) patients are currently being investigated for their potential in breeding wheat crops with reduced toxicity. Aims We evaluated the bread wheat line C173 for its effects on the in vitro -grown duodenal mucosa of CD patients. Methods In vitro -grown duodenal mucosa biopsies of 19 CD patients on a gluten-free diet were exposed to peptic/tryptic-digested prolamins from bread wheat line C173 lacking gliadin–glutenin subunits, analyzed for morphology, cytokine and anti-tTG antibody production, and compared with mucosa biopsies exposed to prolamins from wild-type cv. San Pastore. Results…

Settore MED/09 - Medicina InternaEnterocytemedicine.medical_treatmentAntibodiesTissue Culture TechniquesImmunologic activationInterferon-gammamedicineHumansIntestinal MucosaProlaminCommon wheatTriticumHepatologybiologyGastroenterologyfood and beveragestoxicityimmunologic activation.Interleukin-10Cytokinemedicine.anatomical_structureAnti-transglutaminase antibodiesImmunologyToxicitybiology.proteinInterleukin-2AntibodyGene Deletionwheat plantceliac diseaseProlamins
researchProduct

Extended duration of therapy with peginterferon alpha 2b and weight based ribavirin in HCV patients with genotype 3 infection

2009

Settore MED/09 - Medicina Internatreatmenthepatitis c virugenotype 3peginterferon and ribavirin
researchProduct